EUVIMEDEUVIMED entdecken
Open Access

PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD)

Yuwen Jin iD, Junjie Ding, Xiaohan Hua, Wei Duan, Mo Chen, Zhaohui Zhou, Ramesh V Pandherpur iD, Jin Dong iD, Sharma Pradeep iD, Peiming Ma iD, Weifeng Tang iD, Diansong Zhou iD

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Yuwen Jin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, R&D China, AstraZeneca, Shanghai, China. Hauptthemen laut MEDLINE: Esomeprazole, Gastroesophageal Reflux, Models, Biological, Proton Pump Inhibitors. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esomeprazole, a proton pump inhibitor (PPI), is widely approved for gastroesophageal reflux disease (GERD) in adults and pediatrics globally, but prior to December 2022, its oral tablets (20 and 40 mg) were approved only for adults in China. To address unmet needs in Chinese adolescents aged 12–17 years, physiologically based pharmacokinetic (PBPK) modeling was employed to extrapolate data and support label extension, leveraging similarities in GERD pathophysiology and PK/PD relationships across ages and ethnicities. A PBPK model was developed for esomeprazole to capture the enteric‐coated formulation's pharmacokinetics. The model was validated against clinical PK studies in Caucasian, Japanese, and Chinese adults and/or adolescents, demonstrating good predictions of concentration–time profiles and area under the curve (AUC) for CYP2C19‐specific genotypes as well as overall populations across these ethnic groups. All predicted‐to‐observed ratios for AUC fell within 0.5‐ to 2.0‐fold, with 14 out of 18 predictions within the 0.67‐ to 1.5‐fold. This robust validation enabled the model's application to predict PK in Chinese adolescents. PBPK predictions for Chinese adolescents indicated that steady‐state AUC for 20‐ and 40‐mg doses was comparable to that in Japanese adolescents and slightly higher than in Caucasian adolescents. By integrating an established PK/PD relationship between AUC and the percentage of time with intragastric pH >4, once‐daily doses of 20 or 40 mg were justified, achieving adequate acid suppression with a favorable safety profile. This PBPK‐informed extrapolation was accepted by China's National Medical Products Administration (NMPA), enabling GERD indication extension to adolescents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsomeprazoleGastroesophageal RefluxModels, BiologicalProton Pump InhibitorsAdolescentChildFemaleHumansMaleArea Under CurveChinaCytochrome P-450 CYP2C19GenotypeTablets, Enteric-CoatedWhite PeopleEast Asian People

Stichwörter der Autor:innen

CYP2C19 polymorphismsPBPKesomeprazolepediatric extrapolation

Substanzen

CYP2C19 protein, humanCytochrome P-450 CYP2C19EsomeprazoleProton Pump InhibitorsTablets, Enteric-Coated

Autor:innen und Institutionen

  • Clinical Pharmacology, R&D China, AstraZeneca, Shanghai, China.
  • Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, China.
  • Biometrics and Data Science, R&D China, AstraZeneca, Shanghai, China.
  • Clinical Safety, R&D China, AstraZeneca, Shanghai, China.
  • Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Bengaluru, India.
  • Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.

ORCID-Profile: Yuwen Jin, Ramesh V Pandherpur, Jin Dong, Sharma Pradeep, Peiming Ma, Weifeng Tang, Diansong Zhou

Förderung

  • AstraZeneca

Zitieren

APA

Jin, Y., Ding, J., Hua, X., Duan, W., Chen, M., Zhou, Z., Pandherpur, R. V., Dong, J., Pradeep, S., Ma, P., Tang, W., & Zhou, D. (2026). PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD). The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70255

Vancouver

Jin Y, Ding J, Hua X, Duan W, Chen M, Zhou Z, et al. PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD). The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70255

BibTeX
@article{Jin2026,
  author = {Jin, Yuwen and Ding, Junjie and Hua, Xiaohan and Duan, Wei and Chen, Mo and Zhou, Zhaohui and Pandherpur, Ramesh V and Dong, Jin and Pradeep, Sharma and Ma, Peiming and Tang, Weifeng and Zhou, Diansong},
  title = {PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD)},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70255}
}
Kostenlos starten →